A sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins
- PMID: 3882125
- DOI: 10.1111/j.1365-2133.1985.tb02293.x
A sequential comparison of etretinate (Tigason) and isotretinoin (Roaccutane) with special regard to their effects on serum lipoproteins
Abstract
Etretinate and isotretinoin were compared with respect to their clinical effects and changes in serum lipoprotein concentrations. Sixteen patients with hyperkeratotic and pustular disorders of hands and feet (mainly palmoplantar pustulosis) underwent a double-blind cross-over study. The daily doses of etretinate and isotretinoin were 50 and 40 mg, respectively. Each drug was given for 2 months with a 2-month intermission. The clinical score was reduced both by isotretinoin (P less than 0.05) and etretinate (P less than 0.001). Both drugs affected the lipoprotein concentrations. Isotretinoin increased the cholesterol concentration in low-density lipoprotein (LDL) by 20% and the triglyceride concentration in very low-density lipoprotein (VLDL) by 35%, but decreased the high-density lipoprotein cholesterol by 12%. Etretinate elevated LDL-cholesterol by 10%. These changes had reverted to normal 8 weeks after the end of treatment. The data suggest that in the diseases studied, etretinate is preferable to isotretinoin with regard to both clinical effect and serum lipid side-effects.
Similar articles
-
Plasma fat elimination tissue lipoprotein lipase activity and plasma fatty acid composition during sequential treatment with etretinate and isotretinoin.Acta Derm Venereol. 1987;67(2):139-44. Acta Derm Venereol. 1987. PMID: 2438878 Clinical Trial.
-
A randomized trial of etretinate (Tigason) in palmoplantar pustulosis.Dermatologica. 1983;166(4):220-3. doi: 10.1159/000249872. Dermatologica. 1983. PMID: 6343149 Clinical Trial.
-
Comparative effect of isotretinoin and etretinate on acne and sebaceous gland secretion.J Am Acad Dermatol. 1982 Apr;6(4 Pt 2 Suppl):760-5. doi: 10.1016/s0190-9622(82)70066-0. J Am Acad Dermatol. 1982. PMID: 6461679 Clinical Trial.
-
Retinoids in keratinizing diseases and acne.Pediatr Clin North Am. 1983 Aug;30(4):721-34. doi: 10.1016/s0031-3955(16)34436-4. Pediatr Clin North Am. 1983. PMID: 6193480 Review. No abstract available.
-
Hyperlipidaemia due to isotretinoin and etretinate: possible mechanisms and consequences.Br J Dermatol. 1986 Apr;114(4):401-7. doi: 10.1111/j.1365-2133.1986.tb02842.x. Br J Dermatol. 1986. PMID: 3516195 Review. No abstract available.
Cited by
-
Retinoids increase human apo C-III expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemic action of retinoids.J Clin Invest. 1998 Aug 1;102(3):625-32. doi: 10.1172/JCI1581. J Clin Invest. 1998. PMID: 9691099 Free PMC article. Clinical Trial.
-
Adverse effects of retinoids.Med Toxicol Adverse Drug Exp. 1988 Jul-Aug;3(4):273-88. doi: 10.1007/BF03259940. Med Toxicol Adverse Drug Exp. 1988. PMID: 3054426 Review.
-
Interventions for chronic palmoplantar pustulosis.Cochrane Database Syst Rev. 2006 Jan 25;2006(1):CD001433. doi: 10.1002/14651858.CD001433.pub2. Cochrane Database Syst Rev. 2006. PMID: 16437433 Free PMC article.
-
Pharmacokinetics and therapeutic efficacy of retinoids in skin diseases.Clin Pharmacokinet. 1992 Jul;23(1):42-61. doi: 10.2165/00003088-199223010-00004. Clin Pharmacokinet. 1992. PMID: 1617858 Review.
-
Genetically personalised organ-specific metabolic models in health and disease.Nat Commun. 2022 Nov 29;13(1):7356. doi: 10.1038/s41467-022-35017-7. Nat Commun. 2022. PMID: 36446790 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical